Imugene IUGNF Stock
Imugene Price Chart
Imugene IUGNF Financial and Trading Overview
| Imugene stock price | 0.09 USD |
| Previous Close | 0.09 USD |
| Open | 0.07 USD |
| Bid | 0.06 USD x 1000000 |
| Ask | 0.11 USD x 1500000 |
| Day's Range | 0.07 - 0.07 USD |
| 52 Week Range | 0.06 - 0.65 USD |
| Volume | 50K USD |
| Avg. Volume | 20.23K USD |
| Market Cap | 29.28M USD |
| Beta (5Y Monthly) | 2.361 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IUGNF Valuation Measures
| Enterprise Value | 18.11M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.4241056 |
| Price/Book (mrq) | 0.7373513 |
| Enterprise Value/Revenue | 4.592 |
| Enterprise Value/EBITDA | -0.386 |
Trading Information
Imugene Stock Price History
| Beta (5Y Monthly) | 2.361 |
| 52-Week Change | -78.92% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.65 USD |
| 52 Week Low | 0.06 USD |
| 50-Day Moving Average | 0.1 USD |
| 200-Day Moving Average | 0.18 USD |
IUGNF Share Statistics
| Avg. Volume (3 month) | 20.23K USD |
| Avg. Daily Volume (10-Days) | 22.16K USD |
| Shares Outstanding | 418.31M |
| Float | 278.09M |
| Short Ratio | N/A |
| % Held by Insiders | 12.04% |
| % Held by Institutions | 4.54% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:34 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4736.95% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.21% |
| Return on Equity (ttm) | -111.28% |
Income Statement
| Revenue (ttm) | 3.94M USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -36.00000000000000000000000000000000% |
| Gross Profit (ttm) | 3.94M USD |
| EBITDA | -46916520 USD |
| Net Income Avi to Common (ttm) | -58503144 USD |
| Diluted EPS (ttm) | -0.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.14M USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 4.98M USD |
| Total Debt/Equity (mrq) | 11.89 USD |
| Current Ratio (mrq) | 1.776 |
| Book Value Per Share (mrq) | 0.0949344 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -62889440 USD |
| Levered Free Cash Flow (ttm) | -2783606 USD |
Profile of Imugene
| Country | United States |
| State | NSW |
| City | Sydney |
| Address | 4-6 Bligh Street |
| ZIP | 2000 |
| Phone | 61 2 9423 0881 |
| Website | https://www.imugene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Q&A For Imugene Stock
What is a current IUGNF stock price?
Imugene IUGNF stock price today per share is 0.09 USD.
How to purchase Imugene stock?
You can buy IUGNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Imugene?
The stock symbol or ticker of Imugene is IUGNF.
Which industry does the Imugene company belong to?
The Imugene industry is Biotechnology.
How many shares does Imugene have in circulation?
The max supply of Imugene shares is 418.31M.
What is Imugene Price to Earnings Ratio (PE Ratio)?
Imugene PE Ratio is now.
What was Imugene earnings per share over the trailing 12 months (TTM)?
Imugene EPS is -0.16 USD over the trailing 12 months.
Which sector does the Imugene company belong to?
The Imugene sector is Healthcare.